A kind of aminolevulinic acid hydrochloride liniment
A technology of aminolevulinic acid hydrochloride and powder, which is applied in the field of aminolevulinic acid hydrochloride liniment, can solve the problems of easy recurrence, pigmentation, poor drug safety, etc., and achieve the effect of simple preparation, short course of treatment and mild drug properties
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0023] A kind of aminolevulinic acid hydrochloride liniment, it is made up of powder and solvent two parts, and described powder is 354mg / bottle, and described solvent is 1.5ml / bottle, and the two parts are mixed together when using.
[0024] The powder is aminolevulinic acid hydrochloride;
[0025] The solvent is formed by mixing 602g of ethanol, 50g of sodium lauryl sulfate, 20g of polyethylene glycol 400, 45g of propylene glycol and 600g of pure water.
Embodiment 2
[0027] A kind of aminolevulinic acid hydrochloride liniment, it is made up of powder and solvent two parts, and described powder is 354mg / bottle, and described solvent is 1.5ml / bottle, and the two parts are mixed together when using.
[0028] Among them, ethanol, as a transdermal penetration enhancer and preservative, can increase drug penetration, thereby improving the skin's absorption of drugs, and has a certain antiseptic effect; polyethylene glycol 400 is a good cosolvent, and propylene glycol has moisturizing and antiseptic properties. The role; sodium lauryl sulfate as a surfactant, can promote the penetration of drugs.
[0029] The solvent is formed by mixing 602g of ethanol, 50g of sodium lauryl sulfate, 20g of polyethylene glycol 400, 45g of propylene glycol and 600g of pure water.
[0030] The powder is prepared by mixing aminolevulinic acid hydrochloride and active ingredients of traditional Chinese medicine according to the weight ratio of 3:2,
[0031] The prepa...
Embodiment 3
[0046] clinical information
[0047] 1. standard constrain:
[0048] 1) Age 18-45 years old, both male and female. 2) The onset begins at puberty, and it tends to occur on the face, upper chest and back where the sebaceous glands are developed, and the distribution is symmetrical. The skin lesions are follicular papules, pustules, nodules, cysts, comedones, and scars, with seborrhea and a chronic course. .3) The patient is able to complete the trial and voluntarily signs a written informed consent before the trial begins. 4) Those who have not used too much internal medicine or photosensitive drugs related to the disease within 30 days before treatment;
[0049] This trial was carried out in 4 clinical centers in China, and a total of 117 subjects were randomly enrolled. The median age of the subjects was 22.0 years old, 72 males and 45 females were randomly divided into group 1 with 37 people, group 2 with 40 people, and group 3 with 40 people. Each dose group was basic...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 